These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 21427197

  • 1. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
    La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, Abraldes JG, Bosch J, García-Pagán JC.
    Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
    [Abstract] [Full Text] [Related]

  • 2. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, Payer BA, Trauner M, Peck-Radosavljevic M, Ferlitsch A.
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [Abstract] [Full Text] [Related]

  • 3. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria.
    Merkel C, Bolognesi M, Berzigotti A, Amodio P, Cavasin L, Casarotto IM, Zoli M, Gatta A.
    J Hepatol; 2010 Jan; 52(1):45-53. PubMed ID: 19914730
    [Abstract] [Full Text] [Related]

  • 4. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J, Portal Hypertension Collaborative Group.
    Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
    [Abstract] [Full Text] [Related]

  • 5. Von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis.
    Horvatits T, Drolz A, Roedl K, Herkner H, Ferlitsch A, Perkmann T, Müller C, Trauner M, Schenk P, Fuhrmann V.
    J Hepatol; 2014 Sep; 61(3):544-9. PubMed ID: 24798623
    [Abstract] [Full Text] [Related]

  • 6. Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes.
    Bruha R, Vitek L, Petrtyl J, Lenicek M, Urbanek P, Zelenka J, Jachymova M, Svestka T, Kalab M, Dousa M, Marecek Z.
    Scand J Gastroenterol; 2006 Dec; 41(12):1454-63. PubMed ID: 17101577
    [Abstract] [Full Text] [Related]

  • 7. Clinical, laboratory, and hemodynamic parameters in portal hypertensive gastropathy: a study of 254 cirrhotics.
    Kumar A, Mishra SR, Sharma P, Sharma BC, Sarin SK.
    J Clin Gastroenterol; 2010 Apr; 44(4):294-300. PubMed ID: 19730114
    [Abstract] [Full Text] [Related]

  • 8. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
    Kim MY, Baik SK, Suk KT, Yea CJ, Lee IY, Kim JW, Cha SH, Kim YJ, Um SH, Han KH.
    Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
    [Abstract] [Full Text] [Related]

  • 9. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
    Grønbaek H, Sandahl TD, Mortensen C, Vilstrup H, Møller HJ, Møller S.
    Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
    [Abstract] [Full Text] [Related]

  • 10. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
    Spahr L, Giostra E, Frossard JL, Morard I, Mentha G, Hadengue A.
    Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial.
    Varughese GI, Patel JV, Tomson J, Blann AD, Hughes EA, Lip GY.
    J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis.
    Rincón D, Lo Iacono O, Tejedor M, Hernando A, Ripoll C, Catalina MV, Salcedo M, Matilla A, Senosiain M, Clemente G, Molinero LM, Albillos A, Bañares R.
    Scand J Gastroenterol; 2013 Apr; 48(4):487-95. PubMed ID: 22871085
    [Abstract] [Full Text] [Related]

  • 13. Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis.
    Wang YW, Huo TI, Yang YY, Hou MC, Lee PC, Lin HC, Lee FY, Chi CW, Lee SD.
    J Clin Gastroenterol; 2007 Aug; 41(7):706-12. PubMed ID: 17667056
    [Abstract] [Full Text] [Related]

  • 14. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes.
    Busk TM, Bendtsen F, Nielsen HJ, Jensen V, Brünner N, Møller S.
    Scand J Gastroenterol; 2014 Sep; 49(9):1103-10. PubMed ID: 25048331
    [Abstract] [Full Text] [Related]

  • 15. Liver collagen in cirrhosis correlates with portal hypertension and liver dysfunction.
    Nielsen K, Clemmesen JO, Vassiliadis E, Vainer B.
    APMIS; 2014 Dec; 122(12):1213-22. PubMed ID: 25053449
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis.
    Rincon D, Lo Iacono O, Ripoll C, Gomez-Camarero J, Salcedo M, Catalina MV, Hernando A, Clemente G, Matilla A, Nuñez O, Bañares R.
    Aliment Pharmacol Ther; 2007 Apr 01; 25(7):841-8. PubMed ID: 17373923
    [Abstract] [Full Text] [Related]

  • 17. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.
    Wu H, Yan S, Wang G, Cui S, Zhang C, Zhu Q.
    Scand J Gastroenterol; 2015 Apr 01; 50(9):1160-9. PubMed ID: 25877661
    [Abstract] [Full Text] [Related]

  • 18. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.
    Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, Quehenberger P, Fritzer-Szekeres M, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferlitsch A, Vienna Hepatic Hemodynamic Lab.
    Aliment Pharmacol Ther; 2018 Apr 01; 47(7):980-988. PubMed ID: 29377193
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
    La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, García-Pagán JC, Bosch J.
    J Hepatol; 2009 Aug 01; 51(2):279-87. PubMed ID: 19501930
    [Abstract] [Full Text] [Related]

  • 20. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
    Trebicka J, Krag A, Gansweid S, Appenrodt B, Schiedermaier P, Sauerbruch T, Spengler U.
    Eur J Gastroenterol Hepatol; 2011 Nov 01; 23(12):1218-25. PubMed ID: 21971377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.